Corrigendum to "A six-weekly (Q6W) dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation" [Eur J Canc 131 (2020) 68-75]

Affiliations

• ¹ Quantitative Pharmacology and Pharmacometrics; Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth, NJ, USA.
• ² Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
• ³ University of Toronto, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
• ⁴ Oncology Early Development, Merck & Co., Inc., Kenilworth, NJ, USA.
• ⁵ Clinical Safety and Risk Management, Merck & Co., Inc., Kenilworth, NJ, USA.
• ⁶ Quantitative Pharmacology and Pharmacometrics; Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: [email protected].